| breast cancer - triple negative | ||||||
| es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | |
| immune chekpoint inhibitors | ||||||
| anti-PD-(L)1 | ||||||
| atezolizumab based treatment | ||||||
| atezolizumab plus carboplatin plus nab-paclitaxel | NeoTRIPaPDLA | |||||
| atezolizumab plus nab-paclitaxel | IMpassion-130 ... | IMpassion-130 ... | ||||
| atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | IMpassion-031 ... | IMpassion-031 ... | ||||
| atezolizumab plus paclitaxel | IMpassion-131 ... | IMpassion-131 ... | ||||
| durvalumab based treatment | ||||||
| durvalumab alone | GeparNuevo | |||||
| pembrolizumab based treatment | ||||||
| pembrolizumab alone | KEYNOTE-522 | KEYNOTE-119 ... | KEYNOTE-119 ... KEYNOTE-119 ... | |||
| pembrolizumab plus SoC | KEYNOTE-355 ... | KEYNOTE-355 ... KEYNOTE-355 ... | ||||
Study type:
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
